SAN DIEGO, May 23, 2017 /PRNewswire/ --
Entest BioMedical Inc. (PINK: ENTB) and Its subsidiary, Zander Therapeutics Inc., discussed recently reported progress achieved by Regen BioPharma Inc. (licensor of NR2F6 technology to Zander Therapeutics for veterinary applications) in developing small molecule drugs that activate and inhibit Checkpoint NR2F6.
As the exclusive licensee for veterinary applications of this technology, Zander Therapeutics anticipates a crossover effect for canines with cancer and autoimmune disorders. Because canine DNA is close to human DNA structure, it is believed that advancements by Regen BioPharma will directly impact advancements for Zander Therapeutics in developing small molecule therapies for canine cancer and autoimmune disorders in dogs.
The NR2F6 nuclear receptor has been identified as a potentially extremely important immune cell inhibitor and cancer stem cell differentiator. Molecules which function as immune cell inhibitors are called "immune checkpoints" and basically act as an "on or off switch" to an immune response. Cancer cells sometimes find ways to use these checkpoints to avoid being attacked by the immune system - therefore therapies that target these checkpoints demonstrate tremendous potential as cancer treatments.
The NR2F6 program at Zander Therapeutics is focused on identifying antagonists of NR2F6 in an effort to unleash the cancer-killing potential of a dog's own immune system as well as identifying agonists which should suppress the immune system in diseases where the immune system is over-activated, such as autoimmunity.
"In addition to the data we received on medicinal chemistry optimization, Zander Therapeutics is conducting ex vivo studies using blood samples from dogs. The Company is examining the validity that because dog DNA and human DNA are so close, any human related advancements made by Regen BioPharma should have a positive impact on our canine model for treating dogs with cancer or autoimmune diseases," says David Koos, Ph.D., Chairman & CEO Zander Therapeutics, Inc.
About Zander Therapeutics Inc. and Entest BioMedical Inc.:
Zander Therapeutics is a subsidiary of Entest BioMedical Inc. (OTCPink: ENTB), a publicly traded biotechnology company focused on veterinary medicine. The Company seeks to develop small molecule and immune stimulating therapies for veterinary applications.
Currently, the Company's major interest is in developing small molecule therapies for treating cancer and autoimmune diseases in animals, which include arthritis.
Zander Therapeutics Inc. is the exclusive licensee for veterinary applications of Regen BioPharma Inc.'s (OTCQB: RGBP) (OTCQB: RGBPP) intellectual property and technology relating to NR2F6. NR2F6 is a molecular switch known as a "orphan nuclear receptor", which controls genes associated with the immune response. Zander Therapeutics is solely focused on veterinary applications.
David Koos serves as Chairman and Chief Executive officer of Regen BioPharma, Inc. (OTCQB: RGBP), Entest BioMedical Inc. (OTCPINK: ENTB) and Zander Therapeutics Inc. (subsidiary of Entest BioMedical Inc.).
Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
Zander Therapeutics Inc. and Entest BioMedical Inc.
David R. Koos, Ph.D.
Chairman & Chief Executive Officer
SOURCE Entest BioMedical Inc.